Quarterly ResultMay 7, 2026, 04:12 PM
Annexon Q1 Net Loss $44.1M; Key Clinical Trial Milestones Ahead
AI Summary
Annexon reported a net loss of $44.1 million, or $0.23 per share, for Q1 2026, an improvement from $54.4 million in Q1 2025. The company highlighted significant pipeline progress, including anticipated topline pivotal Phase 3 data for vonaprument in Geographic Atrophy in Q4 2026. Additionally, an EU MAA for tanruprubart for Guillain-Barré Syndrome is under review, with a BLA submission expected in 2026, and Proof-of-Concept data for ANX1502 is also expected in 2026. Annexon maintains a strong balance sheet with $225 million in cash, providing a runway into H2 2027.
Key Highlights
- Topline Phase 3 ARCHER II data for vonaprument in GA expected Q4 2026.
- EU MAA for tanruprubart in GBS under review; BLA submission expected 2026.
- Proof-of-Concept data for ANX1502 in autoimmune conditions expected 2026.
- Q1 2026 net loss was $44.1 million, down from $54.4 million YoY.
- Q1 2026 net loss per share was $0.23, compared to $0.37 YoY.
- Cash, cash equivalents, and short-term investments totaled $225.0 million.
- Anticipated cash runway extends into the second half of 2027.
- R&D expenses decreased to $35.8 million from $48.2 million YoY.
Price Impact
More from ANNX